Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Share-based Compensation (2016 - 2025)

Immucell (ICCC) has disclosed Share-based Compensation for 16 consecutive years, with $73161.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 5.67% year-over-year to $73161.0, compared with a TTM value of $260953.0 through Sep 2025, down 26.97%, and an annual FY2024 reading of $325551.0, down 11.74% over the prior year.
  • Share-based Compensation was $73161.0 for Q3 2025 at Immucell, up from $66714.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $100659.0 in Q4 2023 and bottomed at $23265.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $68266.6, with a median of $68863.0 recorded in 2024.
  • The sharpest move saw Share-based Compensation crashed 58.92% in 2021, then skyrocketed 164.93% in 2022.
  • Year by year, Share-based Compensation stood at $40931.0 in 2021, then soared by 59.77% to $65395.0 in 2022, then skyrocketed by 53.92% to $100659.0 in 2023, then plummeted by 31.59% to $68863.0 in 2024, then increased by 6.24% to $73161.0 in 2025.
  • Business Quant data shows Share-based Compensation for ICCC at $73161.0 in Q3 2025, $66714.0 in Q2 2025, and $52215.0 in Q1 2025.